mutant — TargetMol Chemicals

Cat No.	Product Name	Synonyms	Targets
T16161	Mutant IDH1 inhibitor		Dehydrogenase , Isocitrate Dehydrogenase (IDH)
	Mutant IDH1 inhibitor is an effective inhibitor of mutant IDH1 R132H (IC50: < 72 nM).		Dehydrogenase , Isocitrate Dehydrogenase (IDH)
T2705	Mutant EGFR inhibitor		EGFR
	Mutant EGFR inhibitor is a selective and potent Mutated EGFR inhibitor, inhibits L858R activating mutant, the Exonl9 deletion activating mutant and the T790M resistance mutant.		EGFR
T12128	Mutant IDH1-IN-2		Isocitrate Dehydrogenase (IDH)
	Mutant IDH1-IN-2 is a mutant Isocitrate dehydrogenase (IDH) proteins inhibitor		Isocitrate Dehydrogenase (IDH)
T2043	Mutant IDH1-IN-1	IDH1-IN-1	Dehydrogenase , Isocitrate Dehydrogenase (IDH)
	Mutant IDH1-IN-1 is a potent mutant IDH1 R132 h inhibitor with IC50 < 0.1 uM.		Dehydrogenase , Isocitrate Dehydrogenase (IDH)
T39716	Mutant IDH1-IN-6	Mutant IDH1-IN-6
	Mutant IDH1-IN-6 is an orally active compound that effectively inhibits mutant isocitrate dehydrogenase (IDH) enzymes. It demonstrates potency and selectivity, with IC50 values of 6.27, 3.71, 36.9, and 11.5 nM for IDH1 R...
T12129	Mutant IDH1-IN-4		Others
	Mutant IDH1-IN-4 is an mutant Isocitrate dehydrogenase 1 (IDH 1) inhibitor.		Others
T40272	KRAS mutant protein inhibitor 1
	KRAS mutant protein inhibitor 1 is a KRAS mutant protein inhibitor for potential treatment in cancer.
T11164	EGFR mutant-IN-1		EGFR
	EGFR mutant- in-1, A 5-methylpyrimidopyridone derivative are effective selective EGFRL858R/T790M/C797S mutant inhibitors with IC50 of 27.5 nM, which significantly weakened EGFRWT effect.		EGFR
T12685	RAF mutant-IN-1		Others
	RAF mutant-IN-1 is an inhibitor of RAF kinase(IC50 values of 21 nM, 30 nM and 392 nM for C-RAF 340D/Y341D, B-RAFV600E and B-RAFWT, respectively).		Others
T77805	KRAS G12C mutant protein inhibitor A-1

T64079	Mutant p53 modulator-1
	Mutant p53 modulator-1 is a mutant p53 modulator. mutant p53 modulator-1 is able to hinder the progression of cancers containing p53 mutations.
T9521	CHR-6494 TFA		Others
	CHR-6494 TFA is a potent haspin inhibitor, with an IC50 of 2 nM. It inhibits histone H3T3 phosphorylation. CHR-6494 TFA induces the apoptosis of cancer cells, including melanoma and breast cancer. CHR-6494 TFA can be use...		Others
T8485	THIQ		Melanocortin Receptor
	THIQ is a selective melanocortin-4 receptor (MC4R) agonist (hMC4R and rMC4R with IC50 of 1.2 nM and 0.6 nM , respectively).		Melanocortin Receptor
T16384	Olutasidenib	FT-2102	Dehydrogenase , Isocitrate Dehydrogenase (IDH)
	Olutasidenib (FT-2102) is under the study in the treatment of acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). Olutasidenib is a highly effective, brain penetrant, and selective inhibitor of the mutant Iso...		Dehydrogenase , Isocitrate Dehydrogenase (IDH)
T9246	JNJ-63576253		Androgen Receptor
	JNJ-63576253 is a Clinical Stage Androgen Receptor Antagonist for F877L Mutant and Wild-Type Castration-Resistant Prostate Cancer (mCRPC).		Androgen Receptor
T1921	Alpelisib	BYL-719	PI3K
	Alpelisib (BYL-719) is a PI3Kα inhibitor (IC50=5 nM) with selective, potent, and oral activity. Alpelisib inhibits PI3Kβ/γ/δ with low activity (IC50=250/290/1200 nM). Alpelisib has antitumor activity and is targeted to P...		PI3K
T7414	ARS-853		Apoptosis , Raf , Ras
	ARS-853 is an inhibitor of K-RASG12C(IC50 : 2.5 μM), a mutant form of K-RAS that accumulates in the active GTP-bound state in certain cancer cells		Apoptosis , Raf , Ras
T16143	MRTX-1257		Ras
	MRTX-1257 is a selective, irreversible, and covalent inhibitor of KRAS G12C. It has an IC50 of 900 pM for KRAS dependent ERK phosphorylation in H358 cells. MRTX1257 demonstrated 31% bioavailability in the mouse, with fre...		Ras
T9698	UC2288		Mdm2 , p53
	UC2288 is a relatively selective p21 attenuator which is synthesized based Sorafenib. UC2288 attenuates p21 protein levels with minimal effect on p21 protein stability.		Mdm2 , p53
T9303	MRTX1133		Ras
	MRTX1133 is a KRAS G12D inhibitor (KD=0.2 pM) that is potent, selective, and non-covalent. MRTX1133 exhibits inhibitory activity against KRAS G12D-mutated tumors, but not against KRAS wild-type tumors.		Ras